Biognosys AG. (7/4/11). "Press Release: Deal with Novartis Vaccines and Diagnostics. Siena, Italy – Biognosys Is Entering into a Collaboration with Novartis Vaccines and Diagnostics".

	Organisation	Biognosys AG
	Organisation 2	Novartis Vaccines and Diagnostics Srl
	Group	Novartis (Group)
	Product	Targeted Proteomics technology (Biognosys)
	Product 2	mass spectrometry services (MS services)
	Index term	Novartis–Biognosys: proteomic services, 201104– supply service Targeted Proteomics techn for undisclosed discovery area of Novartis Vaccines Siena

Biognosys AG is entering into a collaboration with Novartis Vaccines and Diagnostics, for which it will apply its proprietary Targeted Proteomics technology platform to an undisclosed discovery area. After having successfully worked for two leading global pharmaceutical companies players in 2010, the newly closed deal with Novartis Vaccines and Diagnostics in Siena is an additional highlight of a successful start into 2011.

Since the company began operations in 2010, Biognosys has provided its targeted proteomics technology to identify and quantify proteins for companies in life sciences and healthcare such as Novartis, Pfizer, Integrated Diagnostics, and Philips.

Record changed: 2011-11-25

Follow Us!

Top News

Upcoming Events

Associations

Partners

Biognosys AG. (7/4/11). "Press Release: Deal with Novartis Vaccines and Diagnostics. Siena, Italy – Biognosys Is Entering into a Collaboration with Novartis Vaccines and Diagnostics".

More documents for Biognosys AG